Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like parsing medical jargon and regulatory code at once—especially when Femasys Inc. details FDA trial phases, device patents, and funding rounds in single documents. If you’ve opened the company’s 10-K only to search for pivotal FemBloc clinical data or revenue from FemaSeed, you’re not alone.
Stock Titan’s AI turns those dense reports into plain language summaries the moment they hit EDGAR. Instantly see which section of the Femasys quarterly earnings report 10-Q filing discusses cash runway, or receive real-time alerts when a director files Femasys insider trading Form 4 transactions. Our platform covers every form:
- 10-K and 10-Q filings—find R&D spend and market-launch timelines with one-click Femasys earnings report filing analysis
- 8-K updates—get Femasys 8-K material events explained, from FDA clearances to patent grants
- DEF 14A proxy—track Femasys proxy statement executive compensation and board governance tied to clinical milestones
- Form 4—monitor Femasys Form 4 insider transactions real-time to gauge executive confidence
Need answers fast? Ask natural questions like “How is FemVue revenue trending?”—our engine replies by linking the exact paragraph in the filing. Whether you’re understanding Femasys SEC documents with AI for due diligence or comparing insider buys via Femasys executive stock transactions Form 4, every disclosure is indexed, summarized, and searchable within minutes. Complex women’s-health innovations deserve clarity; we deliver it, so you can focus on investment decisions instead of page counts.
Femasys (NASDAQ: FEMY) held its Annual Meeting of Stockholders on June 25, 2025, with 59.41% of eligible shares represented. Three key proposals were voted on:
- Director Elections: Two Class I directors were elected for three-year terms through 2028: - Alistair Milnes (4.88M votes for, 941K against) - Edward Uzialko (4.95M votes for, 876K against)
- Equity Incentive Plan Amendment: Stockholders approved increasing authorized shares under the 2021 Plan by 3 million shares (4.26M votes for, 1.58M against)
- Auditor Appointment: KPMG LLP was ratified as independent auditor for FY2025 with overwhelming support (16.10M votes for, 80K against)
The company, listed as an emerging growth company, has elected not to use extended transition periods for new accounting standards compliance.
Femasys Inc. (NASDAQ:FEMY) filed an 8-K announcing a historic milestone with the European approval of FemBloc, their first non-surgical permanent birth control solution. This marks a significant regulatory achievement for the emerging growth company, potentially opening up the European market for their innovative medical device. The announcement was made via press release on June 25, 2025, representing a major development in the company's women's healthcare portfolio.
FAQ
What is the current stock price of FEMASYS (FEMY)?
What is the market cap of FEMASYS (FEMY)?
What is the core focus of Femasys Inc?
How does Femasys generate revenue?
What are the main product categories offered by Femasys?
How does Femasys ensure product quality and safety?
What regulatory approvals have Femasys products received?
How does Femasys differentiate itself from competitors?
